Form 4: Acadia Pharmaceuticals Director Laura Brege Reports Significant Equity Transactions

Acadia Pharmaceuticals Inc. Director Laura Brege reported the exercise of restricted stock units and the grant of new stock options and restricted stock units on May 29, 2025, increasing her beneficial ownership.

Summary

• Laura Brege, a Director at Acadia Pharmaceuticals Inc. (ACAD), filed a Form 4 reporting equity transactions on May 29, 2025.
• She acquired 9,387 shares of common stock through the exercise/vesting of restricted stock units.
• Following this transaction, her direct beneficial ownership of common stock increased to 29,541 shares.
• Additionally, she was granted 13,793 Director Stock Options with an exercise price of $22.29, expiring on May 28, 2035. These options will vest quarterly over one year.
• She also received a grant of 8,107 Restricted Stock Units, which will vest in full on the earlier of one year from the grant date or the next annual meeting of stockholders.

Sentiment

Score: 7

Explanation: The filing indicates routine insider equity transactions, including the vesting of prior awards and the grant of new equity incentives, which is generally a neutral to positive sign as it aligns director interests with shareholders. No negative information is present.

Positives

• Director Laura Brege's beneficial ownership of common stock increased to 29,541 shares, indicating continued alignment with shareholder interests.
• The grant of new stock options (13,793) and restricted stock units (8,107) to a director suggests ongoing commitment and incentivization of key management.

Future Outlook

The vesting schedules for the newly granted stock options (quarterly over one year) and restricted stock units (full vesting on the earlier of one year or next annual meeting) indicate future equity accumulation for the director, aligning their long-term interests with company performance.

Industry Context

This Form 4 filing reflects standard executive compensation practices within the biotechnology and pharmaceutical industry, where equity grants like stock options and restricted stock units are common tools to incentivize and retain directors and executives, aligning their interests with long-term shareholder value creation. Such grants are typical for directors as part of their annual compensation.

Comparison to Industry Standards

• The compensation structure involving stock options and restricted stock units for directors is a common practice across publicly traded companies, particularly in the biotech sector.
• While specific grant sizes vary based on company size, performance, and individual roles, the use of equity-based incentives like those seen for Laura Brege at Acadia Pharmaceuticals is consistent with industry benchmarks for director compensation aimed at fostering long-term alignment with shareholder interests.
• Comparable companies like Biogen Inc. or Gilead Sciences Inc. also utilize similar equity compensation plans for their non-employee directors.

Stakeholder Impact

• Shareholders: The increase in director's beneficial ownership and the grant of new equity incentives align the director's financial interests with long-term shareholder value creation.
• Employees: No direct impact on employees is indicated by this specific filing.

Next Steps

• The newly granted Director Stock Options will vest quarterly over one year following the grant date.
• The newly granted Restricted Stock Units will vest in full on the earlier of one year following the grant date or the next annual meeting of stockholders.

Key Dates

Recommendation

Keywords

Acadia Pharmaceuticals, ACAD, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Director Compensation, Equity Ownership, Laura Brege